InvestorsHub Logo

cosmiclifeform

01/13/06 10:04 PM

#39500 RE: Gcbr #39498

Arch - Computational biology...and the FDA's Critical Path Initiative for accelerating pre-clinical and phase I compounds...

Faster, more efficient trials, saving millions per new drug...and faster to market....

With those and other articles, you've struck a vein of GOLD for DNAPrint's and Biofrontera's pipelines of promising compounds...

Great work...!

God Bless and take care,

Robert





Sav

DorseyE

01/13/06 11:36 PM

#39503 RE: Gcbr #39498

Great stuff Gcbr... thanks!

worktoplay

01/14/06 12:27 AM

#39504 RE: Gcbr #39498

Gcbr...Very nice Arch...thanks. eom

bag8ger

01/14/06 1:12 AM

#39509 RE: Gcbr #39498

Good stuff, arch.

That DNAG needed computational biology in its quiver is the reason Kenna came into our fold.

Their statistical tracking of DNA instructions to RNA and its direction of proteins and enzymes, posed an alluring answer to fill the vacuum left empty by the study of alleles alone.

altarboy4

01/14/06 7:26 AM

#39516 RE: Gcbr #39498

Good article find Arch - hopefully things will finally break sometime this year!

Dnaowner

01/14/06 7:49 AM

#39517 RE: Gcbr #39498

WoW...you da man arch.eom